Cardiovascular, Renal and Metabolic (CVRM) health represents the fastest expanding disease spectrum globally, linking cardiovascular diseases with related comorbidities, such as obesity, diabetes and chronic kidney disease. Due to shared risk factors, a better understanding of patient populations and interconnections of these conditions is needed for the best outcomes.
IQVIA Biotech’s CVRM team understands the unique considerations of planning and executing clinical trials across these three areas. Our combined strength in CVRM expertise, biotech focus and integrated real world data forms a partnership aimed at accelerating the delivery of treatments to patients.
I’m excited to play a part in the cutting-edge research conducted by biotech sponsors and driving progress within CVRM medicine. We take a hands-on approach, engaging clients early to help build innovative program strategies.
With more than 500 CVRM studies in the last 5 years, IQVIA Biotech has been instrumental in assisting biotech companies to meet critical study milestones, expand clinical development worldwide, and maximize patient impact.
For more than 25 years, we have been prioritizing your best interests by providing:
Our dedicated CVRM project management team integrates the IQVIA Biotech clinical program strategy and delivery with IQVIA Centers of Excellence for cardiovascular, nephrology and endocrinology.
Our Cardiovascular Center of Excellence connects your clinical program with scientific and medical expertise, deep therapeutic insights and unrivaled clinical trial experience.
IQVIA brings together exceptional expertise in diabetes across the product lifecycle to help you increase the efficiency of your development program and maximize the value of new therapies.
Renal trials can be challenged by finding the right sites and investigators, slow start-up, and low recruitment and retention rates. Our experienced team is here to help.
Generate and disseminate the right real world evidence (RWE) to meet stakeholder needs with confidence.
Access new resources for advanced therapy development, from candidate identification through market authorization.
Build on our experience of more than 245 rare disease studies in 96 countries to fulfill your promise of hope to millions around the world.